Arbutus to Participate in Two Upcoming Investor Conferences
Arbutus to Participate in Two Upcoming Investor Conferences
WARMINSTER, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Arbutus management team will participate in and host one-on-one meetings at the following two upcoming investor conferences which are being held in New York:
賓夕法尼亞州沃明斯特，2024年5月7日（GLOBE NEWSWIRE）——Arbutus Biopharma Corporation（納斯達克股票代碼：ABUS）是一家臨床階段的生物製藥公司，利用其廣泛的病毒學專業知識爲慢性乙型肝炎病毒（ChbV）感染患者開發功能性治療方法，今天宣佈，Arbutus管理團隊將參加並主持即將舉行的以下兩次投資者會議的一對一會議在紐約舉行：
- The Citizens JMP Life Sciences Conference: Fireside Chat on May 14, 2024 at 9:30 am ET
- H.C. Wainwright 2nd Annual BioConnect Investor Conference: Fireside Chat on May 20, 2024 at 3:30 pm ET
- Citizens JMP 生命科學會議：美國東部時間 2024 年 5 月 14 日上午 9:30 的爐邊談話
- H.C. Wainwright 2和 年度BioConnect投資者大會：美國東部時間2024年5月20日下午 3:30 的爐邊談話
To access the live webcast of the fireside chats please visit: https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.
要觀看爐邊聊天的網絡直播，請訪問： https://investor.arbutusbio.com/events-presentations。活動結束後的有限時間內，將在Arbutus網站上提供網絡直播的存檔重播。
About Arbutus
關於 Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in three Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. For more information, visit www.arbutusbio.com.
Arbutus Biopharma Corporation（納斯達克股票代碼：ABUS）是一家臨床階段的生物製藥公司，利用其豐富的病毒學專業知識來識別和開發具有不同作用機制的新型療法，這些療法可以結合爲慢性乙型肝炎病毒（ChbV）患者提供功能性治癒。我們認爲，成功開發功能性治療方法的關鍵是抑制乙肝病毒DNA、減少表面抗原和增強乙肝病毒特異性免疫反應。我們內部開發的專有化合物產品線包括一種核糖核酸治療藥物 imdusiran (AB-729) 和口服 PD-L1 抑制劑 AB-101。Imdusiran已經生成了有意義的臨床數據，表明它對錶面抗原的減少和乙肝病毒特異性免疫反應的恢復都有影響。Imdusiran目前正在進行三項2a期聯合臨床試驗。AB-101 目前正在 1a/1b 期臨床試驗中進行評估。欲了解更多信息，請訪問 www.arbutusbio.com。
Contact Information
聯繫信息
Investors and Media
投資者和媒體
Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com
麗莎·M·卡佩雷利
投資者關係副總裁
電話：215-206-1822
電子郵件： lcaperelli@arbutusbio.com
譯文內容由第三人軟體翻譯。